Therapeutic aptamers: developmental potential as anticancer drugs

Therapeutic aptamers: developmental potential as anticancer drugs

Aptamers, composed of single-stranded DNA or RNA oligonucleotides that interact with target molecules through a specific three-dimensional structure, are selected from pools of combinatorial oligonucleotide libraries. With their high specificity and affinity for target proteins, ease of synthesis an...

Full description

Saved in:
Bibliographic Details
Published in:BMB reports Vol. 48; no. 4; pp. 234 - 237
Main Authors: Lee, Ji Won, Kim, Hyun Jung, Heo, Kyun
Format: Journal Article
Language:Korean
Published: 2015
Subjects:
Therapeutics
Aptamer
Oligonucleotide
Application
Cancer
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aptamers, composed of single-stranded DNA or RNA oligonucleotides that interact with target molecules through a specific three-dimensional structure, are selected from pools of combinatorial oligonucleotide libraries. With their high specificity and affinity for target proteins, ease of synthesis and modification, and low immunogenicity and toxicity, aptamers are considered to be attractive molecules for development as anticancer therapeutics. Two aptamers - one targeting nucleolin and a second targeting CXCL12 - are currently undergoing clinical trials for treating cancer patients, and many more are under study. In this mini-review, we present the current clinical status of aptamers and aptamer-based cancer therapeutics. We also discuss advantages, limitations, and prospects for aptamers as cancer therapeutics. [BMB Reports 2015; 48(4): 234-237]
Bibliography:KISTI1.1003/JNL.JAKO201523050213728
ISSN:1976-6696
1976-670X